Results 1 to 10 of about 1,327 (120)

Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report [PDF]

Respirology Case Reports
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain.
Takayuki Niitsu, Satoshi Tanaka, Moto Yaga, Makoto Yamamoto, Chika Takahashi, Yoshitaka Usui, Daiki Nagira, Tetsuaki Tsuji, Kento Yokota, Satoshi Tobita, Kiyonobu Ueno   +10 more
doaj   +3 more sources

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy

Biomedicines, 2022
The breakthrough of a limited number of clones while on immune checkpoint inhibitors (ICIs), known as oligoprogression, has been previously described.
Matthew D Galsky, Kunal Sindhu, Michael Buckstein   +2 more
exaly   +3 more sources

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

Frontiers in Oncology, 2022
AimsOligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen ...
Chris Parker, Nina Tunariu, Johann de Bono   +2 more
exaly   +3 more sources

Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade

Cancer Treatment and Research Communications, 2020
Background: While the concept of oligometastatic disease is increasingly recognized as a distinct clinical disease state, the concept of oligoprogression is less well-characterized.
Matthew D Galsky, Danielle Brooks, Amanda Leiter   +2 more
exaly   +3 more sources

Association of salvage radiotherapy with survival outcomes in extracranial oligoprogression after first-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective cohort study [PDF]

Therapeutic Advances in Medical Oncology
Background: While first-line systemic therapy is the standard of care for extensive-stage small-cell lung cancer (ES-SCLC), therapeutic failure remains nearly universal, with survival heavily dictated by progression patterns.
Jiatong Li, Shuting Han, Xiaoyang Zhai, Xuwei Cai, Lujun Zhao, Xuquan Jing, Xiaoyong Tang, Hui Zhu, Jinming Yu   +8 more
doaj   +2 more sources

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial [PDF]

Frontiers in Oncology
Purpose/objectivePatients with metastatic melanoma on active systemic therapy can develop isolated disease progression while the majority of disease remains controlled (oligoprogression).
Oded Icht, Oded Icht, Oded Icht, Alexander Sun, Alexander Sun, Philip Wong, Philip Wong, Andrew McPartlin, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai, C. Jillian Tsai   +17 more
doaj   +2 more sources

Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction The role of metastasis‐directed therapy in urothelial carcinoma remains uncertain, particularly in the immune checkpoint inhibitor era. We report a case of solitary pulmonary metastasis that developed after a favorable response to pembrolizumab and was managed with metastasectomy.
Takemura K, Tanaka M, Hamada Y, Karasaki T, Sakaguchi K, Uruga H, Urakami S, Fujimori S, Uchino K.   +8 more
europepmc   +2 more sources

Acquired resistance to first-line immune checkpoint inhibitors in esophageal squamous cell carcinoma: progression patterns and prognostic implications [PDF]

Frontiers in Immunology
BackgroundDespite the survival benefit of first-line immune checkpoint inhibitor (ICI)-based therapy in advanced esophageal squamous cell carcinoma (ESCC), acquired resistance (AR) remains a major clinical challenge, and its progression patterns and ...
Rui-Ying Zhang, Rui-Ying Zhang, Rui-Ying Zhang, Han Wu, Pei-Xiang Hao, Lu-Lu Guan, Dao Xin, Feng Wang, Feng Wang, Feng Wang   +9 more
doaj   +2 more sources

Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial [PDF]

BMJ Open
Introduction Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second ...
Lei Xu, Rui Feng, Haohua Wang, Jinbo Yue, Fang Shi, Kunli Zhu, Shumei Jiang, Xue Dou   +7 more
doaj   +2 more sources

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression [PDF]

Frontiers in Oncology
Tyrosine kinase inhibitors (TKIs) demonstrate clear therapeutic effects in patients with HER2−positive breast cancer complicated by brain metastases.
Shen Dongxing, Zhu Longyu, Zhang Jun, Kong Deyou, Liu Zhikun   +4 more
doaj   +2 more sources